nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—DAGLB—Effects of PIP2 hydrolysis—DGKH—nephrolithiasis	0.0873	0.158	CbGpPWpGaD
Orlistat—DAGLA—Effects of PIP2 hydrolysis—DGKH—nephrolithiasis	0.0873	0.158	CbGpPWpGaD
Orlistat—Local swelling—Hydrochlorothiazide—nephrolithiasis	0.0334	0.0862	CcSEcCtD
Orlistat—DAGLA—G alpha (q) signalling events—DGKH—nephrolithiasis	0.0175	0.0315	CbGpPWpGaD
Orlistat—DAGLB—G alpha (q) signalling events—DGKH—nephrolithiasis	0.0175	0.0315	CbGpPWpGaD
Orlistat—DAGLB—kidney—nephrolithiasis	0.0162	0.278	CbGeAlD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.0156	0.0282	CbGpPWpGaD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.0156	0.0282	CbGpPWpGaD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.0153	0.0276	CbGpPWpGaD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.0153	0.0276	CbGpPWpGaD
Orlistat—DAGLA—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.0126	0.0228	CbGpPWpGaD
Orlistat—DAGLB—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.0126	0.0228	CbGpPWpGaD
Orlistat—ABHD16A—cortex of kidney—nephrolithiasis	0.0119	0.205	CbGeAlD
Orlistat—FASN—Integration of energy metabolism—CHRM3—nephrolithiasis	0.0118	0.0214	CbGpPWpGaD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.0113	0.0204	CbGpPWpGaD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.0113	0.0204	CbGpPWpGaD
Orlistat—ABHD12—cortex of kidney—nephrolithiasis	0.0112	0.192	CbGeAlD
Orlistat—Urine output increased—Hydrochlorothiazide—nephrolithiasis	0.0106	0.0272	CcSEcCtD
Orlistat—Sleep disorder—Hydrochlorothiazide—nephrolithiasis	0.00979	0.0253	CcSEcCtD
Orlistat—Diabetes mellitus—Hydrochlorothiazide—nephrolithiasis	0.00975	0.0251	CcSEcCtD
Orlistat—Polyuria—Hydrochlorothiazide—nephrolithiasis	0.00966	0.0249	CcSEcCtD
Orlistat—Increased appetite—Hydrochlorothiazide—nephrolithiasis	0.00902	0.0233	CcSEcCtD
Orlistat—Menopausal symptoms—Hydrochlorothiazide—nephrolithiasis	0.00899	0.0232	CcSEcCtD
Orlistat—Thirst—Hydrochlorothiazide—nephrolithiasis	0.00891	0.023	CcSEcCtD
Orlistat—Arthritis—Hydrochlorothiazide—nephrolithiasis	0.00872	0.0225	CcSEcCtD
Orlistat—DAGLA—Hemostasis—DGKH—nephrolithiasis	0.00787	0.0142	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—DGKH—nephrolithiasis	0.00787	0.0142	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—SLC7A9—nephrolithiasis	0.00787	0.0142	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—SLC7A9—nephrolithiasis	0.00787	0.0142	CbGpPWpGaD
Orlistat—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.00777	0.02	CcSEcCtD
Orlistat—Abdominal pain upper—Hydrochlorothiazide—nephrolithiasis	0.00774	0.02	CcSEcCtD
Orlistat—Hypokalaemia—Hydrochlorothiazide—nephrolithiasis	0.00772	0.0199	CcSEcCtD
Orlistat—Breast disorder—Hydrochlorothiazide—nephrolithiasis	0.00766	0.0198	CcSEcCtD
Orlistat—Cramp muscle—Hydrochlorothiazide—nephrolithiasis	0.00764	0.0197	CcSEcCtD
Orlistat—Gastritis—Hydrochlorothiazide—nephrolithiasis	0.0075	0.0193	CcSEcCtD
Orlistat—Abdominal distension—Hydrochlorothiazide—nephrolithiasis	0.00738	0.019	CcSEcCtD
Orlistat—DAGLB—GPCR downstream signaling—RGS14—nephrolithiasis	0.00737	0.0133	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—RGS14—nephrolithiasis	0.00737	0.0133	CbGpPWpGaD
Orlistat—Influenza—Hydrochlorothiazide—nephrolithiasis	0.00733	0.0189	CcSEcCtD
Orlistat—Pancreatitis—Hydrochlorothiazide—nephrolithiasis	0.00718	0.0185	CcSEcCtD
Orlistat—Upper respiratory tract infection—Hydrochlorothiazide—nephrolithiasis	0.00681	0.0176	CcSEcCtD
Orlistat—DAGLA—Signaling by GPCR—RGS14—nephrolithiasis	0.00669	0.0121	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—RGS14—nephrolithiasis	0.00669	0.0121	CbGpPWpGaD
Orlistat—CYP3A4—urine—nephrolithiasis	0.00647	0.111	CbGeAlD
Orlistat—Renal failure—Hydrochlorothiazide—nephrolithiasis	0.00642	0.0166	CcSEcCtD
Orlistat—Neuropathy peripheral—Hydrochlorothiazide—nephrolithiasis	0.0064	0.0165	CcSEcCtD
Orlistat—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.00635	0.0164	CcSEcCtD
Orlistat—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.00613	0.0158	CcSEcCtD
Orlistat—Hepatitis—Hydrochlorothiazide—nephrolithiasis	0.00587	0.0151	CcSEcCtD
Orlistat—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.00582	0.015	CcSEcCtD
Orlistat—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.00578	0.0149	CcSEcCtD
Orlistat—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.00518	0.0134	CcSEcCtD
Orlistat—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.00503	0.013	CcSEcCtD
Orlistat—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.005	0.0129	CcSEcCtD
Orlistat—DAGLA—GPCR downstream signaling—DGKH—nephrolithiasis	0.00498	0.00898	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—DGKH—nephrolithiasis	0.00498	0.00898	CbGpPWpGaD
Orlistat—Back pain—Hydrochlorothiazide—nephrolithiasis	0.00494	0.0127	CcSEcCtD
Orlistat—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00491	0.0127	CcSEcCtD
Orlistat—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.00481	0.0124	CcSEcCtD
Orlistat—PLA2G4A—renal system—nephrolithiasis	0.0048	0.0824	CbGeAlD
Orlistat—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.00474	0.0122	CcSEcCtD
Orlistat—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.00467	0.012	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—ADCY10—nephrolithiasis	0.00465	0.00839	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—ADCY10—nephrolithiasis	0.00465	0.00839	CbGpPWpGaD
Orlistat—Malaise—Hydrochlorothiazide—nephrolithiasis	0.0046	0.0119	CcSEcCtD
Orlistat—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.00459	0.0118	CcSEcCtD
Orlistat—DAGLB—Signaling by GPCR—DGKH—nephrolithiasis	0.00452	0.00816	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—DGKH—nephrolithiasis	0.00452	0.00816	CbGpPWpGaD
Orlistat—PLA2G4A—cortex of kidney—nephrolithiasis	0.00452	0.0776	CbGeAlD
Orlistat—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00451	0.0116	CcSEcCtD
Orlistat—Cough—Hydrochlorothiazide—nephrolithiasis	0.00446	0.0115	CcSEcCtD
Orlistat—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00435	0.0112	CcSEcCtD
Orlistat—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.00435	0.0112	CcSEcCtD
Orlistat—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.00433	0.0112	CcSEcCtD
Orlistat—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.0043	0.0111	CcSEcCtD
Orlistat—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.00425	0.011	CcSEcCtD
Orlistat—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00417	0.0107	CcSEcCtD
Orlistat—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.00417	0.0107	CcSEcCtD
Orlistat—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00403	0.0104	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—RGS14—nephrolithiasis	0.00395	0.00713	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—RGS14—nephrolithiasis	0.00395	0.00713	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—GRHPR—nephrolithiasis	0.00392	0.00707	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—ADCY10—nephrolithiasis	0.00385	0.00695	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.00384	0.00694	CbGpPWpGaD
Orlistat—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.0038	0.00979	CcSEcCtD
Orlistat—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00377	0.00972	CcSEcCtD
Orlistat—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00374	0.00965	CcSEcCtD
Orlistat—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00367	0.00946	CcSEcCtD
Orlistat—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00362	0.00934	CcSEcCtD
Orlistat—DAGLB—GPCR downstream signaling—CHRM3—nephrolithiasis	0.0036	0.00649	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—CHRM3—nephrolithiasis	0.0036	0.00649	CbGpPWpGaD
Orlistat—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00359	0.00926	CcSEcCtD
Orlistat—Pain—Hydrochlorothiazide—nephrolithiasis	0.00356	0.00919	CcSEcCtD
Orlistat—PNLIP—Disease—SLC26A1—nephrolithiasis	0.00354	0.0064	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—AGXT—nephrolithiasis	0.00349	0.0063	CbGpPWpGaD
Orlistat—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00343	0.00885	CcSEcCtD
Orlistat—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00341	0.00879	CcSEcCtD
Orlistat—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00331	0.00854	CcSEcCtD
Orlistat—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00329	0.00849	CcSEcCtD
Orlistat—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00329	0.00849	CcSEcCtD
Orlistat—DAGLB—GPCR downstream signaling—PTH—nephrolithiasis	0.00329	0.00594	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—PTH—nephrolithiasis	0.00329	0.00594	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—RGS14—nephrolithiasis	0.00327	0.00591	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—CHRM3—nephrolithiasis	0.00327	0.0059	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—CHRM3—nephrolithiasis	0.00327	0.0059	CbGpPWpGaD
Orlistat—PNLIP—Disease—ATP6V0A4—nephrolithiasis	0.00316	0.0057	CbGpPWpGaD
Orlistat—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00307	0.00792	CcSEcCtD
Orlistat—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00299	0.00771	CcSEcCtD
Orlistat—DAGLA—Signaling by GPCR—PTH—nephrolithiasis	0.00299	0.00539	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—PTH—nephrolithiasis	0.00299	0.00539	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—SLC26A1—nephrolithiasis	0.00297	0.00536	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—APRT—nephrolithiasis	0.00297	0.00536	CbGpPWpGaD
Orlistat—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00295	0.0076	CcSEcCtD
Orlistat—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00285	0.00735	CcSEcCtD
Orlistat—FASN—Metabolism—GRHPR—nephrolithiasis	0.00277	0.005	CbGpPWpGaD
Orlistat—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00276	0.00711	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00267	0.00482	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00267	0.00482	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—DGKH—nephrolithiasis	0.00267	0.00482	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—DGKH—nephrolithiasis	0.00267	0.00482	CbGpPWpGaD
Orlistat—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00265	0.00683	CcSEcCtD
Orlistat—Rash—Hydrochlorothiazide—nephrolithiasis	0.00263	0.00677	CcSEcCtD
Orlistat—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00263	0.00677	CcSEcCtD
Orlistat—Headache—Hydrochlorothiazide—nephrolithiasis	0.00261	0.00673	CcSEcCtD
Orlistat—FASN—Disease—SLC26A1—nephrolithiasis	0.00251	0.00453	CbGpPWpGaD
Orlistat—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00248	0.00638	CcSEcCtD
Orlistat—FASN—Metabolism—AGXT—nephrolithiasis	0.00247	0.00446	CbGpPWpGaD
Orlistat—FASN—Disease—ATP6V0A4—nephrolithiasis	0.00223	0.00403	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—DGKH—nephrolithiasis	0.00221	0.00399	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00221	0.00399	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—AQP1—nephrolithiasis	0.00211	0.00382	CbGpPWpGaD
Orlistat—FASN—Metabolism—APRT—nephrolithiasis	0.0021	0.00379	CbGpPWpGaD
Orlistat—FASN—Metabolism—SLC26A1—nephrolithiasis	0.0021	0.00379	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—DGKH—nephrolithiasis	0.00198	0.00358	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—SLC7A9—nephrolithiasis	0.00198	0.00358	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CHRM3—nephrolithiasis	0.00193	0.00348	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CHRM3—nephrolithiasis	0.00193	0.00348	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—CHRM3—nephrolithiasis	0.00191	0.00345	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PTH—nephrolithiasis	0.00176	0.00319	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PTH—nephrolithiasis	0.00176	0.00319	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—RGS14—nephrolithiasis	0.00168	0.00304	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CHRM3—nephrolithiasis	0.0016	0.00289	CbGpPWpGaD
Orlistat—CYP3A4—renal system—nephrolithiasis	0.00158	0.0272	CbGeAlD
Orlistat—CYP3A4—kidney—nephrolithiasis	0.00153	0.0263	CbGeAlD
Orlistat—FASN—Metabolism—AQP1—nephrolithiasis	0.0015	0.0027	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PTH—nephrolithiasis	0.00146	0.00264	CbGpPWpGaD
Orlistat—FASN—Metabolism—CHRM3—nephrolithiasis	0.00135	0.00244	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—SLC26A1—nephrolithiasis	0.00123	0.00223	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GRHPR—nephrolithiasis	0.00119	0.00215	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ADCY10—nephrolithiasis	0.00117	0.00211	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—DGKH—nephrolithiasis	0.00114	0.00205	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—AGXT—nephrolithiasis	0.00106	0.00191	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—RGS14—nephrolithiasis	0.000994	0.00179	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—APRT—nephrolithiasis	0.000901	0.00163	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—SLC26A1—nephrolithiasis	0.000901	0.00163	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—SPP1—nephrolithiasis	0.000886	0.0016	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—SPP1—nephrolithiasis	0.000886	0.0016	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CHRM3—nephrolithiasis	0.000822	0.00148	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PTH—nephrolithiasis	0.000752	0.00136	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—SPP1—nephrolithiasis	0.000734	0.00133	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000671	0.00121	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—DGKH—nephrolithiasis	0.000671	0.00121	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—AQP1—nephrolithiasis	0.000642	0.00116	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CHRM3—nephrolithiasis	0.000581	0.00105	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CHRM3—nephrolithiasis	0.000485	0.000876	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PTH—nephrolithiasis	0.000444	0.000802	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GRHPR—nephrolithiasis	0.000278	0.000503	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AGXT—nephrolithiasis	0.000248	0.000448	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SPP1—nephrolithiasis	0.000223	0.000402	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SLC26A1—nephrolithiasis	0.000211	0.000381	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—APRT—nephrolithiasis	0.000211	0.000381	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AQP1—nephrolithiasis	0.00015	0.000271	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CHRM3—nephrolithiasis	0.000136	0.000245	CbGpPWpGaD
